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Omar S HajjawiAbstract
In many respects, the most remarkable chemical substances within the genome of eukaryotic cells are remarkable
proteins which are the critical structural and functional units of living cells. The specifications for everything that
goes in the cell are natural digital-to-digital decoding process in an archive sequence by deoxyribonucleic acid
(DNA) and an articulate construction by ribonucleic acid (RNA). The products of DNA transcription are long polymers of
ribonucleotides rather than deoxyribonucleotides and are termed ribonucleic acids. Certain deoxyribonucleotide
sequences, or genes, give rise to transfer RNA (tRNA) and other ribosomal RNA (rRNA) when transcribed. The
ribonucleotide sequences fold extensively and rRNA is associated with specific proteins to yield the essential cell
components, ribosomes. Transcription of other special sequences yields messenger RNAs (mRNAs) that contain
ribonucleotide sequences that will be ultimately translated into new types of amino acid sequences of functional
cellular protein molecules. This switch to a different variety of cellular molecular sequences is complex, but each
sequence of the three ribonucleotides specifies the insertion of one particular amino acid into the polypeptide
chain under production. Whilst mRNA is considered the vehicle by which genetic information is transmitted from
the genome and allocated in the appropriate cytoplasmic sites for translation into protein via cap-dependent
mechanism, the actual translation depends also on the presence of other so-called household and luxury protein
molecules. Recent evidence suggests RNA species are required at initiation, because treatment of cells with
antibiotics or drugs that inhibit RNA synthesis cause a decrease in protein synthesis. The rRNA is necessary as a
structural constituent of the ribosomes upon which translation takes place, whereas tRNA is necessary as an
adaptor in amino acid activation and elongation protein chains to ribosomes. In this article, we review malignant
tumor, with stem like properties, and recent technical advances into the phenomenon of micro-particles and
micro-vesicles containing cell-free nucleic acids that circulate plasma. New areas of research have been opened
into screening tumor telomerase progression, prognosis of aptamers targeting cell surface, monitoring the efficacy
of anticancer therapies, oncogenic transformation of host cell, and RNA polymerases role in the cell cycle progression
and differentiation.
Keywords: Polymerases, Polyadenylation, Ribosomal RNA, Telomerase RNA, Aptamers, Carcinogenesis, Genometastasis,
Antineoplastic agents, Signal Transducer and Activator of Transcription-STAT, Drug resistanceIntroduction
Rudolf Virchow (1821–1902) is generally credited as the
first to recognize leukemia cells [1], and Fridrich
Miescher (1844–1895) had identified and isolated cellu-
lar substance containing nitrogen and phosphorus,
whereas Albrecht Kossel (1853–1927) isolated the nu-
cleic acids: two purines (adenine and guanine) and three
pyrimidines (thymine, cytosine and uracil) [2]. Cancer isCorrespondence: omar.hajjawi@aauj.edu
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unless otherwise stated.however defined as a group of more than 100 different
diseases that is caused by multiple changes in cellular
DNA and RNA, and it is characterized by uncontrollable
growth (mitosis) in which cells are aggressive, invasive
and sometimes metastatic [3]. Also, the discovery of the
double helix of DNA molecule by Watson and Crick [4]
was an added milestone in the twentieth century science
(Figure 1). The genetic material of living organisms and
double helix of DNA molecule formed the foundation of
new discipline of molecular biology.is an Open Access article distributed under the terms of the Creative Commons
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Figure 1 The essential single strand RNA and two strands DNA nucleic acids.
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pairs that cover a distance of 34 Ǻ (3.4 nm). The individ-
ual base pairs are spaced 34 Ǻ (3.4 nm) apart. The places
where the strands cross hide base pairs that extend per-
pendicular to the viewer. The inside diameter is 11 Ǻ
(1.1 nm), and the outside diameter 20 Ǻ (2.0 nm).
Within the cylindrical outline of the double helix are
two grooves that are large enough to house polypeptide
chains. The largest human chromosome, chromosome
number 1, consists of approximately 220 million base
pairs and is 85 nm long. The minus signs alongside the
double helix strands represent many negatively charged
phosphate groups along the entire length of each strand.
Unlike double-stranded DNA, RNA is a single-stranded
molecule in many of its biological roles and has a much
shorter chain of nucleotides. However, RNA can, by
complementary base pairing, form intra-strand double
helixes, as in tRNA. While DNA contains deoxyribose,
RNA contains ribose (in deoxyribose there is no hy-
droxyl group attached to the pentose ring in the 2′ pos-
ition). These hydroxyl groups make RNA less stable
than DNA because it is more prone to hydrolysis. Thecomplementary base to adenine is not thymine, as it is
in DNA, but rather uracil, which is a nunmethylated
form of thymine.
Adopted from: Watson J.D. and Crick, F.H.C. (1953)
“Molecular structure of nucleic acid. A structure of
deoxyribosenucleic acid”, Nature, vol.171, pp.737-738;
Gregory, S., Barlow, K.F., McLay, K.E., Kaul, R., Swarbreck,
D., Dunham, A., Scott, C.E., Howe, K.L. and Woodfine,
K. (2006). “The DNA sequence and biological annota-
tion of human chromosome 1”. Nature, vol. 441 (7091),
pp.315–221; Nelson, D.L. and Cox, M.M. (2008) Lehninger
Principles of Biochemistry, 5th edn, pp.277-287. New York,
NY: W.H. Freeman and Company.
The detailed mechanism by which such genetic material
could be expressed as the structural and catalytic proteins
which play so important a role in the functioning of all
living cells was still not obvious [5-7]. Stanley miller
(1930–2007) and Harold Urey (1893–1981) designed an
experiment that simulated hypothetical conditions thought
to be present at the time of early life on earth [8,9] and
tested qualitatively for the occurrence of earthly chemicals
that originated life [10]. The essential chemical elements
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sterile glass flasks and tubes, were subjected to electric
discharges and the interaction produced 20 amino acids,
the building block of proteins, as well as other organic
compounds like: adenosine triphosphate, lipids, some
sugars and the bases for RNA and DNA (Lazcano and
Bada [11,12]).
Crick et al. [13] designed an elegant experimental
strategy to determine the nature of the genetic code that
was remarkably the correct one despite the absence of
technology to analyze and compare DNA and protein
sequence. The genetic code is the relation between the
bases sequence in DNA (or its RNA transcripts) and
amino acids sequence in proteins [14]. The features of
the genetic code are as follows: (1) three nucleotide en-
code an amino acid, (2) the code is nonoverlapping, (3)
the code has no punctuation, and (4) the genetic code is
degenerate [14-16].
Proline only differs from this basic structure as it con-
tains an unusual ring to the N-end amine group, which
forces the CO–NH amide moiety into a fixed conform-
ation [17,18]. Once this conceptual breakthrough had
been made, the complex task of unraveling the many
steps in protein biosynthesis could begin in the laboratory
[19]. The sequence of amino acids in a protein is defined
by a gene and encoded in the genetic code. Although
this genetic code specifies 20 different L-α-amino acids,
the residues in a protein are often chemically altered in
post-translational modification: either before the pro-
tein can function in the cell, or as part of control mech-
anisms [17,20].
Genes are made of nucleic acids that contain the in-
structions for making proteins; enzymes are also made
of proteins and they are needed to replicate genes [21-25].
Genetic information encoded in the two complemen-
tary strands of the DNA of any structural gene is tran-
scribed by an enzyme called DNA-dependent RNA
polymerase that catalyzes the synthesis of RNA from a
DNA or RNA template [26]. The eukaryotic RNA poly-
merases (pol-I [27], pol-II [28] and pol-III [29,30] are
the central multiprotein machines. The DNA-dependent
RNA polymerase makes a single stranded RNA copy,
complementary to one of the strands that are called
mRNA. This attaches to a subcellular organelle ribo-
some which is composed of two subunits between 25
and 30 nm (250–300 Å) in diameter with an rRNA to
rotein ratio that is close to 1 [18,19]. It operates as a
black box upon which the mRNA is translated [31,32].
The term translation encompasses all the steps by which
the genetic content of the mRNA contained in the linear
sequence of ribonucleotides is converted into a linear se-
quence of amino acids [26]. Whilst mRNA might be con-
sidered the means whereby genetic information is actually
transmitted from the genome (the DNA), and placed inthe appropriate cytoplasmic sites for translation into pro-
tein [33]. Organelle biogenesis and maintenance requires
newly synthesized proteins, each of which needs to go
from the ribosome translating its mRNA to the correct
translocation to an organelle sub compartment [34].
Interestingly, it was demonstrated that fat and obesity-
associated gene is located on chromosome 16 of
mRNA demethylase [E.C. 2.1.1.270], i.e. methylation of
mRNA plays a critical role in human energy homeosta-
sis [35-37].
The nucleic acids are assembled from individual nucle-
otides just as proteins are assembled from individual
amino acids. The nucleotides are synthesized by a series
of enzyme mediated-mediated reactions [26,38,39]. Bio-
chemical pathways are separately pursued for the syn-
thesis of the ribose and the different bases that are then
assembled to form nucleotide triphosphates [40]. The
energy-carrying molecule ATP which consists of the
base adenine, ribose, and three phosphate groups is also
one of the nucleotide building blocks used in the synthe-
sis of RNA, and the others being guanosine triphos-
phate, cytidine triphosphate and uridine triphosphate
[41]. These nucleotides are usually synthesized by the
transfer of energy from ATP to their diphosphate forms
of the nucleotides [18]. Thus, there is a general pool of
nucleotide triphosphates that work as building blocks
for RNA within the cell [42,43]. These free nucleotides
assembled into a linear sequence where the RNA mol-
ecule contains some of the coded information that is
present in DNA, and when the DNA is copied into
mRNA using base pairing of adenine-thymine, and
guanine-cytosine is the process of DNA transcription
[14]. During the synthesis of mRNA, the bonds between
these pairs in DNA, adenine-thymine and guanine-
cytosine, and the double- stranded structure partially
unwinds and the two strands separate [18]. The bases of
the free nucleotide triphosphates and the bases in one of
the separated DNA chains form new bonds. DNA there-
fore acts as a template to command the sequence of the
bases in RNA. The base adenine in the free nucleotide
would pair with the base thymine in DNA, and the base
uracil in the free nucleotide would also pair with the
base adenine in DNA. Similarly, the base cytosine in the
free nucleotide pairs with the base guanine in DNA, and
the base guanine in the free nucleotide pairs with base
cytosine in DNA [44]. The resulting outcome would be
a new sequence of bases in RNA which is an enantiomer
mirror image of the base sequence in DNA [43]. Since
the primary advantage of nucleotide base-pairing is that
DNA two strands can replicate easily and accurately,
each base can only pair to one other base (thymine to
adenine, adenine to thymine, cytosine to guanine, and
guanine to cytosine). Thus, if the original DNA codon
contains the base sequence cytosine-guanine-thymine,
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cytosine-adenine [45-48].
Once the appropriate free nucleotide triphosphates are
base-paired to the corresponding bases in DNA, the nu-
cleotides are joined to each other by the enzyme RNA-
polymerase II (12 subunits) that causes pyrophosphate
to be split off from nucleotide triphosphate in the
process of linking one nucleotide to the next, forming
the sugar-phosphate backbone of mRNA [43,49,50]. This
enzyme is active only in the presence of DNA and it
does not link the free nucleotide triphosphates together
in its absence [46]. The enzyme moves along the DNA
strand, linking one nucleotide at a time into the growing
mRNA chain [47,51]. RNA-polymerase II activity is
DNA-dependent, meaning that it must have a DNA
template molecule before it can synthesize the RNA
transcript. The DNA-dependent polymerase must also
have Mg2+ and ribonucleoside 5′ triphosphates in order
to carry out RNA synthesis. The RNA polymerase cre-
ates the new RNA strand from 5′ to 3′ [48].
Protein expression is determined by the rate of tran-
scription and by post transcription processes that lead to
changes in the mRNA transport, stability and translation
efficiency [52]. These post-transcriptional processes are
mediated by RNA modifications, secondary structure,
micro RNAs (miRNAs), and RNA-binding proteins that
recognize regulatory elements located in the 3′ untrans-
lated regions of transcripts [53]. The critical cellular
process of polyadenylation that is the addition of poly
(A) tail to mRNA that plays important roles in many as-
pects of the cellular metabolism of mRNA, though it be-
gins as the transcription of a gene finishes or terminates.
The 3′-most segment of the newly made pre-MRNA is
first cleaved off by a set of proteins; these proteins then
synthesize the poly (A) tail at any one of several possible
sites [54]. The cleavage generates the free 3′-hydroxyl
group that defines the end of the mRNA to which aden-
ine residues are immediately added by polyadenylate
polymerase that catalyzes the reaction:
RNA þ nATP W RNA AMPð Þn þ nPPi
where n = 200–250 [18,55]. The poly (A) tail and its
associated proteins are more likely to ptotect mRNA
from enzymic destruction [56]. Protein-coding genes
may have more than one polyadenylation site, “extra
RNA”, so a gene can code for several mRNAs that differ
in their 3′-end [57], though mRNA polyadenylation is
controlled by various cis-acting elements surrounding
the cleavage site and their binding factors. Since alterna-
tive polyadenylation changes the length of the 3′ un-
translated region, global shortening of 3′ untranslated
regions through alternative polyadenylation is an emer-
ging hallmark of cancer [58,59]; it can also change whichbinding sites for miRNAs the 3′ untranslated region
contains [60]. So, polyadenylation is a way of marking
the RNA for degradation for many non-coding RNAs,
including tRNA, rRNA,snRNA and snoRNA [61]. The
RNA exosome (30-100 nm) is a conserved degradation
machinery, which obtains full activity only when associ-
ated with cofactors; poly (A) tails have been found on
human RNA fragments of both homopolymeric and
mostly heterpolymeric tails [61-63]. Regulated polyade-
nylation of specific mRNAs is involved in oogenesis, cell
cycle progression and synaptic plasticity [64]. Many
polyadenylation trans-acting factors, including polyade-
nylate polymerase, are increasingly found to be involved
in cell cycle, apoptosis and cancer prognosis [65]. So,
genes undergoing alternative cleavage and polyadenyla-
tion during human cancer progression may be useful
novel biomarkers and potentially targeted for disease
prevention and treatment [66,67].
The micro RNAs are an endogenous class of post-
transcriptional regulators that regulate as many as one-
third of human genes; they are small in length (21–25
nucleotide-long fragments) and single stranded [68].
Studies suggest that approximately half of known micro-
RNA reside in non-protein coding RNAs (intron and
extron) or within the intron of protein coding genes
[68,69]. They can recognize and bind to imperfect base-
pairing complementary sequences in the 3′-untranslated
region of multiple target mRNAs, blocking translation of
the gene expression or inducing cleavage of mRNA to
control a multitude of critical processes through either
reduction or inhibition in the translational efficiency of
the target mRNA [70,71]. Recent studies have shown
that miRNAs are aberrantly expressed in various human
diseases, ranging from cancer to cardiovascular hyper-
trophy [72]. The micro RNAs target ~60% of all genes,
and they are abundantly present to repress 100 s of tar-
gets in all human cells; bioinformatics indicates that a 22
nucleotide single stranded RNA composed of 4 different
ribonucleotides, they can have over 1013 possible se-
quence combinations. So, since the cell contains typic-
ally ~1049 miRNAs, there must be a very high
developmental and evolutionary selection pressure that
utilizes only specific miRNA oligonucleotide sequences
to yield biologically useful miRNA-mRNA interactions
[73]. The biogenesis of miRNA is similar to other RNA
starting from DNA transcription. A primary miRNA is
an independent transcript processed by RNA polymerase
II and they are bound in the nucleus by the ‘micropro-
cessor’ complex that consists of ribonuclease III (an Mg2
+-dependent endonuclease), Drosha, and its co-factor,
Pasha (DGCR8) [74]. The generation of mature miRNAs
from precursor miRNAs by the ribonuclease III (Dicer1
/TRBP complex in the cytoplasm [75]. Dicer is a special-
ized ribonuclease that initiates RNA interference by
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[76], and TRBP (the human immunodeficiency virus
transactivating response to double strand RNA-binding
protein) is an integral component of a Dicer-containing
complex [75,76].
Neoplasia that includes many diseases is an abnormal-
ity of cellular differentiation, maturation and control of
growth [77]. Rupert Allan Willis (1898–1980) defined
neoplasm as “an abnormal mass of tissue, the growth of
which exceeds and is uncoordinated with that of the sur-
rounding normal tissues and persists in the same exces-
sive manner after cessation of the stimuli that evoked
the change”, and this definition is the widely cited one
[29]. Also, several neoplastic and non-neoplastic diseases
were shown to contain circulating nucleic acids and that
in cancer they originate mostly from tumor [78]. Hence,
the level of circulating nucleic acids that have been asso-
ciated with tumor burden and malignant progression,
are utilized for cancer screening, prognosis, and moni-
toring the efficacy of an anticancer therapy [79].
Also, Conrad H. Waddington (1905–1975) had re-
ported an intricate interplay between the cellular envir-
onment and genes effects on phenotype determination;
he attributed the molecular signals to epigenetic
phenomenon [80-82]. The epigenetic signals that areFigure 2 The fundamentals process of information transfer in cells.responsible for the establishment, maintenance and the
reversal of metastable transcriptional states, have direct
correlation with promoter hypermethylation and si-
lenced tumor suppressor genes, upstream transcription
factors and DNA repair enzymes [83,84]. Since cancer is
ultimately a disease of genes, the mechanism by which
epigenetic information is transmitted through cell div-
ision remain unclear as the complex epigenetic states
are orchestrated by several converging signals [84-86].
The biologically active RNAs, including mRNA, tRNA,
rRNA, small nucleic RNAs, [87] and other non-coding
RNAs [64], contain self-complementary sequences that
allow parts of the RNA to fold [88-90] and pair with it-
self to form double helices (Figure 2).
The analysis of these RNAs has revealed that they are
highly structured and they do not consist of long double
helices but rather collections of short helices packed to-
gether into structures akin to proteins. RNAs fold and
conform to enzyme chemical catalysis [88,91,92], for ex-
ample, the active site of ribosome that analyzes peptide
bond formation and release consists entirely of RNA
[87,93]. The rRNA is necessary as a structural compo-
nent of ribosomes upon which translation actually takes
place and tRNA is required in amino acid activation, as
an adaptor in mRNA directed amino acid specification
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somes (Figure 2). In the process of DNA transcription
the positioning of nucleotide units in the RNA mole-
cules being made is under the control of the DNA that
acts as a template [18,94]. The means by which this tem-
plate dictates such a sequence involves both base pairing
interactions and specific interactions between proteins
and nucleic acids [95]. Each RNA chain is initiated at a
specific site on the DNA template and subject to ter-
mination at another unique type of site on the tem-
plate, i.e. there are defined units of transcription
[41,96]. It is a selective process. Specific signals in the
DNA template are recognized by the transcription ap-
paratus. Initiation is governed by promoter regions in
the DNA, and the region governing termination is des-
ignated a terminator [97].
(1) Transcription: Information encoded in the nucleo-
tide sequence of DNA is transcribed through synthesis
of mRNA whose sequence is dictated by the DNA se-
quence. (2) Translation: As the sequence of mRNA is
decoded by the protein synthesis machinery, it is trans-
lated into the sequence of amino acids in a protein. This
information transfer is encapsulated in the dogma:
DNA→ RNA→ Protein.
Adopted from: Hernández, G. (2012) On the Emergence
and Evolution of the Eukaryotic Translation Apparatus, in
Cell-Free Protein Synthesis, Biyani, M. (ed.), p.32. Re-
trieved September13, 2014 from http://cdn.intechopen.
com/pdfs-wm/39965.pdf.
Archibald Garrod (1857–1936) was one of the first sci-
entists to propose that inherited factors (genes) con-
trolled the function of proteins [51]. Defects (diseases)
in metabolism could be linked to the failure of specific
enzymes to catalyze essential biochemical reactions. Pro-
tein synthesis, translation, is directed by an mRNA mol-
ecule. Translation can be seen to occur in two phases:
(1) information transfer, in which RNA base sequence of
the mRNA determines the sequence of amino acids and
(2) chemical processes, in which the peptide bonds
between the adjacent amino acids are formed. The
components required for translation include: mRNA, ri-
bosomes (60S and 40S), tRNA, aminoacyl tRNA synthe-
tases, and accessory proteins involved in initiation,
elongation and termination [18,80]. Elongation can be
thought to involve three processes: (1) aligning each
aminoacylated tRNA, (2) forming the peptide bond to
add the new amino acid to the polypeptide chain, and
(3) moving the ribosome along the mRNA by three more
bases (one codon). Elongation proceeds until a stop
codon is reached. There are three stop codons in the
genetic code: UAG, UGA, UAA [98].
It is exceptionally difficult to assess the carcinogenic
effects of so many agricultural, industrial, and household
chemicals, but a significant hazard is posed by thedisposal of various agricultural and industrial wastes that
may contaminate drinking water, coastal water and mar-
ine life pollution [99-101]. Also, the identification of a
chemical carcinogen is problematic because of the long
lag between chemical exposure and the development of
cancer, unless the effect is dramatic [102,103]. In view of
the vast number of chemical substances that people en-
countered during their lives, Table 1 shows most
strongly evidenced carcinogenic chemicals.
Virus is an ultramicroscopic virion wrapped in pro-
tective coating of protein, infectious agent, obligate
intracellular parasites whose replication depends on its
core DNA or RNA and protein synthetic process of the
host cell for growth in tissue culture [104]. The major
pathogenic of viruses are adenoviridae, flaviviridae,
hepadnaviridae, herpesviridae, homyxoviridae, papovavir-
idae, paramyxoviridae, picornaviridae, polyomaviridae,
orthomyxoviridade, rhabdoviridae and togaviridae [105].
The viral infection commonly reaches optimal time as a
function of replication as clinical symptoms appear
[106] , and the replication consists of the following
steps: (1) attachment to and penetration of susceptible
cell, (2) disassembly of nonstructural proteins to make
nucleic acid available for virus multiplication, (3) synthesis
of RNA or DNA through transcription and translation
(Figure 2), (4) synthesis of structural and functional pro-
teins, and (5) assembly and release mature viral particles
from the cell [81,104]. Table 2 shows antiviral chemical
agents that would clinically block virus replication
when they are administered on the inset of disease, i.e.
chemoprophylaxis.
Methodology
On infection, a viral RNA permeates human host cell
membranes, whereupon it is either destroyed by several
cellular RNases [E.C.3.1.26.4 RNase H; E.C. 3.1.26.5
RNase P; E.C. 3.1.27.3 RNase T1; E.C. 3.1.27.1 RNase T2;
E.C. 3.1.27.4 RNase V2; E.C.3.1.27.8. RNase V1 and
others], or it binds to ribosomes and it grows and di-
vides to make proteins at an unregulated quickened pace
[107,108]. The process of transcription cycle that con-
sists of: preinitiation, initiation,promoter clearance,
elongation and termination have a significant impact on
the growth potential of tumours [109]. The failure of the
host cell to recognize and destroy the viral infection is
caused by the lack of particular co-stimulated molecules
that aid in the way antigens react with lymphocytes
[110-112]. Hence, the basic research into cancer entails
identification of causes and developing strategies for pre-
vention, diagnosis, treatments and cure [113-116]. The
research spans chemotherapy, hormone therapy, im-
mune therapy, nanomaterials, palliative surgery, radi-
ation therapy and combined treatment modalities
[77,94,117-121]; and the methods of evaluation were
Table 1 Major chemical carcinogens in humans
No. Chemical carcinogen
1 Aflatoxin - B1 [CAS:1162-65-8] & Aflatoxin - G1 [CAS:1165-39-5]: A group
of toxic polynuclear (benzenoid type) metabolite molds produced
chiefly by the fungus Aspergillus flavus; they are natural contaminants
of a wide range of fruits, vegetables, cereal grains and improperly
stored food. The B1and G1 strains are known carcinogens
2 Aromatic amines [CAS: 8007-70-3]: Benzidine-based and naphthyamine
are procarcinogens examples that enter the body through the skin, lungs
or intestine. The gradation of potency of the carcinogenic amines
depends on their hydrophobicity, and on electronic (reactivity,
propensity to be metabolically transformed) and steric properties
Azo dyes [CAS: 84812-61-3]: Any of a broad series of synthetic dyes
that have –N = N- as a chromophore group. They are widely used
in the food, pharmaceutical, cosmetic, textile and leather industries.
3 Asbestos [CAS: 1332-21-4]: A group of impure magnesium silicate
minerals which occur in fibrous form. The various types serpentine,
amphibole, amosite and crocidolite are highly toxic by inhalation
of dust particles
4 Chemotherapeutic agents: Cytotoxic chemicals that are selectively
destructive to malignant cells and tissues. They are classified into
antimetabolites, anti-tumour, anthracyclines, topoisomerase inhibitors,
plant alkaloids, and alkyting agents which are considered most
important because they can add alkyl groups to the many electronegative
groups under conditions which are present in some cells to modify















Soot [CAS: 98615-67-9]: An airborne powder made of amorphous carbon,
whereas its gas phase contains polycyclic aromatic hydrocarbons.
Tobacco [CAS: 8037-19-2]: Cured leaves of the species Nicotiana tabacum
that contains acids (citric, oxalic, formic), alkaloids (nicotine, anabasine,
myosmine), carbohydrates (lignin, pentosans, starch, sucrose), as well
as tannin, ammonia, glutamine, and micro amounts of zinc, iodine,
copper, manganese and polonium 84Po210. Cigarette tar contains
various aromatic ring compounds (especially benzo-[a] oyrene).
7 Vinyl chloride [CAS: 75-01-4]: CH2 = CHCl,
It is a manufactured substance that is used to prepare polyvinyl
chloride to make plastic products for use in food packaging,
medical products, appliances, cars, toys, credit cards and rainwear,
and leaches into air and water.
The chemicals listed are those for which strong evidence exists.
Source: Chandrasoma, P. and Taylor, C.T. (2000) Concise Pathology, 3rd edn.
East Norwalk, CT: Appleton& Lange; Kumar, V., Abbas, A.K. and Aster, J.C.
(2014) Robins and Cotran Pathologic Basis of Disease, 9th edn. Philadelphia,
PA: W.B. Saunders.
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ational cytology), (2) flow cytometry, (3) hystological
methods, (4) immunohistochemistry, (5) molecular diag-
nosis (aptamers), (6) tumor markers (hormones (calci-
tonin, catecholamine & metabolites, ectopic, human
chronic gonadotropin-HCG), oncofetal antigens (α-fetal
protein, carcino embryonic antigen), iso enzymes, spe-
cific proteins, mucins and glycoproteins, new molecular
markers).
RNA phage of each step of protein synthesis that
could be possible to control, is indicative of individual
inter-related biosynthesis of a given protein [122]. The
rate of initiation complex formation dictates the amount
of each of the viral proteins [98,123]. The RNA polymer-
ases begin to replicate the viral RNA, a process of the
most central mediators of malignant transformation
[32,124]. RNA polymerase I [125], RNA polymerase II
[50,126,127] and RNA polymerase III [128,129] tran-
scribe protein-coding genes and they interact with fac-
tors involved in the synthesis of precursor rRNA 45S,
chromatin remodeling, transcriptional activation, elong-
ation, and RNA processing.
The multicellular eukaryotic human enzymes can be
purified using isolated organelle, like nucleus, nucleoli,
mitochondria and other internal organelles as a starting
material, though simultaneous recovery of all three RNA
polymerases is not always feasible due to diffusible na-
ture of some of nuclear enzymes [18,110]. Jacob and
Rose [130] had extensively reviewed the methods of
solubilization, purification and difficulties of mammalian
RNA polymerases.
HeLa cells were often the source for RNA polymerase
complexes [131]; mitotic cells and cancer tissues with
corresponding normal tissues that can be collected and
frozen in liquid nitrogen at −80°C, are viably preserved
until essayed [127,132]. Histopathological examination is
done on the 10% formalin-fixed, paraffin-embedded
tissue specimens which is an invaluable resource for
clinical research though the nucleic acids extracted are
fragmented and chemically modified making them challen-
ging to use in molecular studies [133-135]. Histopatho-
logical observations are utilized in progression, metastatic
susceptibility, therapeutic and radiation therapy sensitivity
and prognosis [136,137]. Interestingly, the Raman spec-
troscopy non-invasive technique enables the observation
of intracellular biological molecules without fixation or la-
beling procedures in situ [137,138].
The bicinchoninic acid kit protein quantification assay
[139] that is widely used to determine protein concentra-
tions in the region 25-2000 μg/ml. The cells are sus-
pended and lysed in hypotonic buffer (20 mM Tris–HCl
[pH 7.5], 1 mM CaCl2, 1 mM MgCl2, 1 mM ZnCl2 con-
taining 1% Triton X-100) for 5 min on ice; they were then
separated into nucleolar and nucleoplasmic fractions by
Table 2 Antiviral agents and some of their properties
Drug Description Used for
Purine and Pyrimidine
analogues
Atripla An antiretroviral contains non-nucleoside (efavirenz) and
two nucleosides (emtricitabine and tenofovir disoproxil
fumerate) reverse transcriptase inhibitor.
A fixed-dose regimen or in combination with other
antiretroviral drugs (rifampin) for the treatment of HIV
infection.
Azidothymidine: Combivir An anti-HIV drug containing nucleoside reverse transcriptase
inhibitors, containing zidovudine and lamivudine.
In combination with other antiretroviral drugs for
treatment of immunodeficiency for HIV infection.
Retrovir A nucleoside reverse transcriptase. In combination with other retroviral drugs to treat HIV
infection.
Trizvir An antiretroviral, nucleoside reverse transcriptase inhibitor. In combination with other drugs for treatment of HIV
infection.
Complera An antiretroviral contains non-nucleoside (rilpivirine) and
two nucleosides (emtricitabine and tenofovir disoproxil
fumerate) reverse transcriptase inhibitor.
A fixed-dose regimen or in combination with other
antiretroviral drugs for the treatment of HIV infection.
Cymevene An antiviral preparation which is a DNA polymerase
inhibitor, containing ganciclovir.
Cytomegalovirus-CMV in AIDS patients with reduced
immunity.
Emtriva A nucleoside reverse transcriptase inhibitor that contains
emtricitabine.
In combination with other antiretroviral drugs for
treatment of HIV infection. It is similar to lamivudine and
cross-resistance between the two is near similar.
Epivir A nucleoside reverse transcriptase inhibitor, containing
lamivudine.
In addition to other antiretroviral drugs to control and
treat HIV infection.
Harvoni A nucleoside reverse transciptase inhibitor that contains
both ledipasvir and sofosbuvir.
An antiviral drug to treat chronic Hepatitus C.
Herpid An antiviral preparation containing idoxuridine. Skin infections caused by Herpes zoster and Herpes
simplex.
Hivid A nucleoside reverse transcriptase inhibitor, containing
zalcitabine.
A combination therapy with antiretroviral drugs for
treatment of HIV infection.
Lamivudine: Combivir A nucleoside reverse transcriptase inhibitor that contains
both lamivudine and zidovudine.
In combination with other antiretroviral drugs for
treatment of HIV infection.
Epivir A nucleoside reverse transcriptase inhibitor. In combination with other antiretroviral drugs for
treatment of HIV infection and disease.
Trizivir A nucleoside reverse transcriptase inhibitor that contains
both lamivudine and zidovudine.
In combination with other antiretroviral drugs for
treatment of HIV infection.
Zeffix A nucleoside reverse transcriptase inhibitor. Chronic Hepatitis B and evidence of viral replication in
patients with liver disease, inflammation and fibrosis.
Rebetol An antiviral preparation that contains tribavirin. In combination with interferon (pegintron) for the
treatment of chronic Hepatitis C.
Stribild An antiretroviral tablet contains non-nucleoside (elvitegravir)
integrase strand transfer inhibitor, mechanism-based inhibitor
of cytochrome P450 (cobicistat) and two nucleosides
(emtricitabine and tenofovir disoproxil fumerate) reverse
transcriptase inhibitor.
A fixed-dose regimen for the treatment of HIV infection
in adults who are antiretroviral treatment-naïve.
Videx A nucleoside reverse transcriptase inhibitor that contains
didanosine.
In combination with other antiretroviral drugs for
treatment of HIVinfection.
Vira-A An antiviral medication that contains vidarabin. Ointment treatment caused by Herpes simplex. It is an
alternative to acyclovir.
Viracept An antiviral protease inhibitor that contains nelfinavir. In addition to other antiretroviral drugs for treatment of
HIV infection.
Viread An antiviral nucleotide analogue that contains tenofivir. In combination with other retroviral drugs for treating
Hepatitis B and HIV infected patients with virological
failure.
Virgan An antiviral eye gel preparation that contains ganciclovir. Acute inflammation of cornea, keratitis.
Viroptic An antiviral medication that contains trifluridine. Eye drops treatment caused by mild viral infection.
Zeffix A nucleoside analogue that contains lamivudine. Chronic Hepatitis B and evidence of viral replication in
patients with liver disease, inflammation and fibrosis.
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Zerit A nucleoside reverse transcriptase inhibitor that contains
stavudine.
In combination with other antiretroviral drugs for
treatment of HIV infection.
Zovirax An antiviral DNA polymerase inhibitor that contains
acyclovir.
Treatment and suppression of infections of skin and
mucous membranes caused by Herpes simplex, Herpes
zoster and varicella.
Other drugs
Abacavir : Trizivir An antiretroviral,nucleoside reverse transcriptase inhibitor
that contains abacavir, lamivudine and zidovudine.
In combination with other antiretroviral drugs for the
treatment of HIV infection.
Ziagen A nucleoside reverse transcriptase inhibitor. In combination with other antiretroviral drugs for treating
HIV infection.
Amanatadine hydrochloride: A viral replication inhibitor. Treatment and prevention of influenza A.
Lysovir A dopaminergic, tricyclic amine preparation. Parkinsonism.
Symmetral
Dolutegravir An antiretroviral, integrase strand transfer inhibitor. Treatment of HIVinfection in conjunction with other
antiretroviral drugs.
Foscavir A DNA polymerase inhibitor that acts in two stages to
suppress the replication of cytomegalovirus; it contains
foscarnet.
Life-threatening infections of viral origin especially those
of eyes in AIDS patients with cytomegalovirus retinitis.
Also, infections of mucous membranes and skin caused
by Herpes simplex and AIDS patients who have not
responded to treatment with acyclovir.
Gamma globulin: A preparation of human normal immunoglobulin (5%). Immunoglobulin replacement therapy in patients who
are immunodeficient, including, including various
inherited disorders like hypogammaglobulinaemia (low
levels of gammaglobulin in blood),
agammaglobulinaemia (absence of gammaglobulin in
blood). Also, thrombocytopenia purpera (bleeding
disorder), and helping to prevent recurrent infection by
HIV infection.
A preparation of human normal immunoglobulin (16%).
Flebogamma A preparation of human normal immunoglobulin, freeze-
dried powder comprising 0.5 g, 2.5 g, 5.0 g and 10.0 g in
bottles with diluents for reconstitution and injection.
Gammabulin A preparation of human normal immunoglobulin (5%). Antibody deficiency syndrome.
A freeze-dried preparation of human normal
immunoglobulin.
Guillain-Barre syndrome (a severe,often rapidly
progressive syndrome of muscular weakness and
paralysis, believed to be an autoimmune disease),
Kawasaki syndrome (a disorder affecting lymph nodes),
thrombocytopaenia purpera (a clotting disorder involving
blood platelets).
Gammagard A preparation of human normal immunoglobulin,
available as a solution and powder
Replacement in various immunodeficiency states,
including certain congenital conditions like
thrombocytopaenia purpera. Also, prevention of recurring
bacterial infections with HIV, Guillain-Barre syndrome,
Kawasaki syndrome.
OctagamSandoglobulinVigam Replacement treatment in primary and secondary
immunoglobulin deficiencies, prevention of bacterial
infections in children born with AIDS, thrombocytopenic
purpura, Kawasaki disease, bone marrow transplants,
Guillain-Barre syndrome.
Vigam Primary agammaglobulinaemia,
hypogammaglobulinaemia, and other secondary
secondary immunodeficiency disorders in children with
AIDS,thrombocytopenia purpura,Kawasaki disease,bone
marrow transplants and Guillain Barre syndrome
Interferons alfa: Introna A single-subtype recombinant preparation in powder. Neoplastic disorders (malignant conditions).
Roferon-A A preparation of interferon alfa-2a in a solution. Hepatitis B and Hepatitis C (with or without tribavirin),
neoplastic disorders.
Viraferon A preparation of interferon alfa-2b ina solution. Chronic Hepatitis B and chronic Hepatitis C infections.
Interferons beta: Betaferon A preparation acting on the immune system. Relapsing-remitting multiple sclerosis, and secondary
progressive multiple sclerosis.
Rebif An immunimodulator of interferon beta-1a. Multiple sclerosis with relapses.
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Interferons Gamma: Immukin A preparation of recombinant human interferon gamma- Ib. Additional treatment (with antibiotics) to lessen the
incidence of serious infections acquired by patients with
chronic granulomatous disease (any disese that gives rise
to masses of granulation tissue, e.g.tuberculosis and
leprosy).
Paclitaxel A taxoid antineoplastic agent and mitotic inhibitor that is
based on plant alkaloid taxane or 11 (15- > 1) abeotaxane.
Treatment of tumor cancers: breast, ovarian, lung,
bladder, prostate, melanoma, esophageal and Kaposi
sarcoma.
Rifadin An antibiotic and antimalarial preparation that contains
rifampicin.
Prevention of meningococcal meningitis, carriers of
Haemophilus influenza, additional therapy for brucellosis,
Legionnaire’s disease and serious staphylococcal
infections, tuberculosis and mycobacterial infections,
leprosy.
Triumeq An antiviral medication that contains a non-nucleoside
integrase strand transfer inhibitor (dolutegravir), and two
nucleoside reverse transcriptase inhibitors (abacavir and
lamivudine).
A single-pill regimen for treatment HIV infection.
Viramune A non-nucleoside reverse transcriptase inhibitor that contains
nevirapine.
In combination with other antiretroviral drugs for
treatment HIV infection, progressive and/or advanced
immunodeficiency.
Both DNA and RNA viruses can cause neoplasia. DNA viruses insert their nucleic acid directly into the genome of host cell and the virus replication normally
ensues. Examples: Papilloma, Herpes simplex, Molluscum contagiosum,and Hepatitis B. RNA viruses require RNA-directed DNA polymerase (reverse transcriptase),
an enzyme that causes production of a DNA copy of the RNA viral genome. Retroviruses examples: human T lymphocyte virus type I- HTLV-I, acquired immune
deficiency syndrome –AIDS, human immunodeficiency virus –HIV.
Adopted from: Medicines & Prescription Drugs [102] New Lanark,ML: Geddes & Grosset; Pisano, D.J. and Mantus, D.S. (2008) FDA Regulatory Affairs: A Guide for
Prescription Drugs, Medical Devices and Biologics, 2nd edn. New York, NY: Informa Healthcare USA, Inc.; Katzung, B.G., Masters, S.B. and Trevor, A.J. (2011) Basic &
Clinical Phamacology, 12th edn. New York, NY: McGraw-Hill Medical Division.
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15 min at 4°C, and the supernatant was collected and fro-
zen at −20°C until re-use [50,132]. This method is a modi-
fied form of the Lowry et al. [141] and Bradford [142]
methods that are also widely used dye-binding chromo-
genic protein variations assays [143]. The Bradford [142]
protein assay is based on the association of specific amino
acid residues, arginine, lysine, and histidine, with non-
conjugated groups of Coomassie brilliant blue G-250 dye,
in an acidic environment. When the dye-protein complex
is formed, the pKa of the red-brown acidic solution con-
verted to blue and it measured at 595 nm. Bradford dye is
convenient protocol to use, fast and relatively sensitive,
but several compounds can interfere with the assay
against typical standard curves for bovine serum albumin
and bovine gamma globulin [144]. The other Lowry et al.
[141] protein assay lies in the formation of peptide nitro-
gen(s) complex with Cu2+ under alkaline conditions
(pH 10.0-10.5), and the subsequent reduction of the Folin-
Ciocalteay phosphomolybdic phosphotungstic acid re-
agent to heteropolymolybdenum blue at spectra 750 nm,
though ethylenediaminetetraacetic acid (EDTA) can inter-
fere with chromophore production [145].
Radio-immunohistochemistry is a very sensitive in
vitro technique in which a traceable radioactive isotope
tags a marker to detect, identify and quantitate the con-
centration of specific ochemical neoplasia substance(s)
[134,146-149]. Radioimmunoassay has been developed
to identify and quantitate the concentration of RNApolymerase I [150], RNA polymerase II [151], RNA poly-
merase III [152] and mRNA [153]. Although it is less
sensitive than enzymic activity as a measure of reverse
transcriptase, but it can detect antigen using minute
amounts of protein and in the presence of inhibitors for
an RNA tumor virus-producing cells [154].
The three RNA polymerases transcribe the genome in
the cell nuclei. The RNA polymerase II that is respon-
sible for synthesizing mRNA and a large variety of non-
coding RNAs, is mostly important; RNA production in
growing cells is carried out by RNA polymerase I that
transcribes the precursor of large rRNA, and by RNA
polymerase III that transcribes rRNA, tRNA, and some
noncoding RNAs [155]. Hossenlopp et al. [156] have
used anti-polymerase I serum to classify the three RNA
polymerases in order of their inhibition: I > III > I, indi-
cating that polymerases I and II are more closely related
than polymerases I and II [32,157].
Findings and interpretations
The differential effect of selective inhibition on nuclear
and nucleoplasmic RNA sysnthesis is related to the ex-
istence of distinct nuclear and chromosomal RNA
polymerases that cause mitotic-like biochemical and
morphological responses. Also. ribosome synthesis in
HeLa cells is shown to be controlled at the level of pro-
cessing rather than at the level of 45S RNA transcription
where chemical agents would cause the physiological and
structural transitions of viral mitosis [158,159]. Table 2
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ered to interfere with the process of virus replication.
In conclusion, the advent of sequencing human gen-
ome has facilitated the impressive advances in diagnosis,
prognosis and treatment methodologies of invasive hu-
man tumor cells. A new area of research into chemical
agents that interfere with mitosis-related cell death
(apoptosis), are able to denature chemotherapy resistant
neoplastic cells and inhibit protein expressions. Giri and
Kumar [55,160] have reported that the over expression
of neo-poly (A) polymerase in human cancer cells signi-
fies the importance of polyadenylation in cancer cellular
events. The specificity of an electrostatic interaction be-
tween RNA and natural alkaloids or their synthetic ana-
logs is found to be capable of inducing self-structure in
polyadenelation. Hence, new novel compounds that ex-
hibit excellent binding affinity to many RNA structures,
can be utilized to modulate poly (A) structure in devel-
oping RNA targeted cancer therapeutics [161,162]. The
nanoparticles of aptamers are also emerging to target
the reaction of specific antigen epitopes with their bind-
ing sites. These are promising techniques in clinical
diagnosis and therapy. Such new insights into genetics
of tumors have prompted ground-breaking insights into
development of new drugs that can treat, shrink and
coax given tumors into prolonged remission.
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